IRVINE, Calif., Dec. 1, 2006 (PRIME NEWSWIRE) -- "The drug eluting stent has become a battlefield of sorts in the medical technology marketplace," stated SmallCap Sentinel analyst D.R. Clark. "Companies are looking to enhance the efficacy of drug eluting stents and some recent results are compelling."
"Along these lines, MIV Therapeutics Inc. (OTCBB:MIVT), a leading developer of next-generation biocompatible drug-eluting stents, announced this week that a comparative animal study of two of its novel polymer-free drug-eluting stent coating technologies has concluded with positive results," Clark added. "The study compared stents coated with MIVT's polymer-free drug-eluting technologies to the J&J Cypher(tm) stent, one of the world's best selling drug-eluting stents and successfully demonstrated that both of MIVT's proprietary, polymer-free, Sirolimus eluting coatings are at least as good as Johnson & Johnson's Cypher(tm) Stent."
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Boston Scientific CP (NYSE:BSX). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/autoir/mivt_autoir.html
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Companies interested in being featured in SmallCap Sentinel should reach us using the contact info below or sts@marketpathways.com
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a 45 day period. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.